| Code | CSB-RA614514MB4HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to CMK-389, targeting interleukin-18 (IL-18), a pro-inflammatory cytokine belonging to the IL-1 superfamily. IL-18 plays a critical role in both innate and adaptive immune responses by inducing interferon-gamma production and promoting Th1 cell differentiation. This cytokine is involved in the regulation of inflammatory processes and has been implicated in various pathological conditions, including autoimmune diseases, inflammatory bowel disease, rheumatoid arthritis, and metabolic disorders such as obesity and type 2 diabetes. Elevated IL-18 levels have also been associated with cardiovascular disease and certain malignancies, making it an important target for immunological research.
CMK-389 serves as the reference standard for this biosimilar antibody, providing researchers with a cost-effective alternative for investigating IL-18-mediated signaling pathways and disease mechanisms. This antibody is suitable for studies exploring cytokine networks, inflammatory responses, and the therapeutic potential of IL-18 modulation in various disease models. It represents a valuable tool for immunology and inflammation research applications.
There are currently no reviews for this product.